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Abstract
Though the approach used to classify chronic respiratory diseases is changing to a treatable-traits
(TT) approach, data regarding very elderly patients is lacking. The objectives of this study were to
assess TT frequency in very elderly patients and to study the link between extrapulmonary TTand
ventilatory defects. Individuals (˜75 years) residing in elderly care centres answered a standar-
dised questionnaire, underwent spirometry, atopy and fractional exhaled nitric oxide assessments
and had their blood pressure and peripheral pulse oximetry measured. Pulmonary, extrapulmon-
ary and behavioural TT were evaluated. Outcome variables were an airflow limitation (post-
bronchodilator z-score FEV1/FVC\21.64) and a restrictive spirometry pattern (z-score FEV1/
FVC ˜ + 1.64 and z-score FVC\21.64). Seventy-two percent of the individuals who took part
in the study (n = 234) were women, and the median age of participants was 86 (IQR: 7.4). At least
one pulmonary TT was identified in 105 (44.9%) individuals. The most frequent extrapulmonary
TTs were: persistent systemic inflammation (47.0%), anaemia (34.4%), depression (32.5%) and
obesity (27.4). Airflow limitation was exclusively associated with smoking (OR 5.03; 95% CI 1.56–
16.22). A restrictive spirometry pattern was associated with cognitive impairment (OR: 3.89; 95%
CI: 1.55–9.79). A high frequency of various TTs was found. The novel association between a
restrictive spirometry pattern and cognitive impairment highlights the urgency of clinical research
on this vulnerable age group.
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Introduction
Population ageing is the triumph of advances made in public health, medicine and
economic and social development over diseases that have limited human lifespans
throughout history.1 According to the United Nations’ publication ‘World
Population Prospects of 2019’, by 2050, one in six people (16%) in the world will
be over the age of 65, up from one in 11 in 2019 (9%).1 In some regions, like
Europe and North America, by 2050, one in four people are predicted to be over
the age of 65.1 Furthermore, the number of people aged 80 or over is projected to
triple, from 143million in 2019, to 426million in 2050.1 Unfortunately, despite the
growing percentage of older people in the population, they remain underrepre-
sented in clinical research.2 This is particularly true for those living with multimor-
bidity, frailty or dementia and those who live in care homes.2 With the growing
phenomenon of population ageing, the need for robust, high-quality health
research that includes older people has never been greater,2 as the extrapolation of
data and treatment recommendations from studied to unstudied populations can
result in catastrophic consequences and increased costs.3
Chronic respiratory diseases (CRDs) are common, and – relatively – increasing,
causes of disability and death.4 The physiologic, cellular and immunologic changes
that occur due to ageing contribute to the development of lung disease.5 Although
the prevalence of CRDs has been increasing as the population ages, it may still be
underestimated in older persons.5
The concept of disease classification in CRDs has changed considerably in recent
years.6,7 Standard classifications based on symptoms, signs and functional abnorm-
alities are being substituted by the treatable trait approach,6,7 a label-free, precision
medicine approach to the diagnosis and management of CRDs.6 This approach is
based on identifying treatable traits in each patient, which might be treatable based
on ‘phenotypic’ recognition or a deep understanding of the critical causal path-
ways.6 Treatable traits are divided into the following categories: pulmonary, extra-
pulmonary and behavioural/lifestyle risk factors.6 From a patient perspective, it is
important to recognise that each patient may have more than one treatable trait,
and that, in fact, many do. One of the potential strengths of this approach is that it
does not rest on the assumption that the diagnosis (e.g. asthma or chronic obstruc-
tive pulmonary disease) is well-established and clear, circumstances that not often
the case in clinical practice. In elderly patients, the issue might be particularly perti-
nent as typical symptoms of CRDs can often also have non-pulmonary origins.8
The treatable traits approach relies on specific diagnostic criteria being defined for
these ‘traits’, which may have a considerable impact on patient treatment should
the more favourable therapeutic response expected be evidenced.6 Information
about the interrelations between treatable traits is lacking. This fact is particularly
evident in very elderly patients and ventilatory defects.
The aim of this study was to investigate the frequency of treatable traits in a gen-
eral population of very elderly individuals and to find the link between extrapul-
monary and behavioural/lifestyle risk factors and ventilatory defects.
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Methods
Study design, setting and participants
The OLDER (Obstructive Lung Diseases in the Elderly) study took place in
Lisbon, Portugal. It was an observational study, divided into three phases. This
study shall report results from Phase I, which took place between April and
December 2016, and within which residents of 15 elderly care centres (ECC) in
Lisbon were invited to participate. In Phase I, besides undergoing spirometry, frac-
tional exhaled nitric oxide (FeNO) and atopy assessments, participants answered
standardised questionnaires and blood samples were collected. In this Phase, every
participant also performed a peripheral pulse oximetry.
To be eligible for the OLDER study, participants were required to be ˜65 years
of age, present with cognitive and collaboration capabilities sufficient to perform a
spirometry and not have any contraindications for lung function testing. The sam-
ple size was calculated so as to estimate the frequency of participants with a forced
expiratory volume in the 1st second/forced vital capacity (FEV1/FVC) of \0.70.
According to data published about the Portuguese population, a prevalence of
30% was estimated for this age group. For a confidence level of 95% and a margin
of error of 4.5%, it was calculated that 293 participants would have to be studied.
According to experience gained in a previous study,9 it was considered that about
70% of ECC residents would not meet the inclusion criteria. In order to achieve
the target number, plans were made to screen 1000 residents. This paper shall ana-
lyse the very elderly patients (˜75 years) included in the study.
The procedures followed were in accordance with the World Medical
Association’s Code of Ethics (Declaration of Helsinki). The database was regis-
tered with the Portuguese Data Protection Authority. The OLDER study was
approved by NOVA Medical School’s Ethics Committee, Portugal (no. 38/2015/
CEFCM). The elderly study participants and their caregivers were informed about
the study and gave their signed consent.
Data sources for health assessment
Questionnaires
In Phase I, participants answered Portuguese versions of standardised questionnaires
administered by one single, trained interviewer. These were: (1) The Burden of
Obstructive Lung Disease initiative (BOLD) questionnaire,10,11 (2) St. George’s
Respiratory Questionnaire (SGRQ),12 (3) Mini-Mental State Examination
(MMSE)13,14 and (4) 15-item Geriatric Depression Scale (GDS-15).15,16 Authorisations
from the authors of these questionnaires were obtained when required.
Lung function tests
A spirometry with bronchodilatation test was administered and FeNO
measurement taken by a trained respiratory therapy technician, as per
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recommendations.17,18 The spirometry was performed using a portable pneumota-
chograph (Vitalograph Compact, Vitalograph, Buckingham, UK) and the FeNO
using a portable analyser (Niox Vero, Aerocrine, Solna, Sweden). Because spiro-
metric manoeuvres have been shown to transiently reduce exhaled nitric oxide lev-
els, FeNO analyses were performed before spirometry tests.18 Bronchodilation test
patients received 400mg of inhaled salbutamol, administered via a metered-dose
inhaler in a spacer. A spirometry test was then repeated after 15min.17 Spirometry
results were interpreted alongside the reference equations of the Global Lung
Function Initiative 2012.19 Spirometry values were only considered valid if all tech-
nical standards were achieved and once validated by a committee of experts made
up of medical doctors and health technicians.
Atopy assessment
Atopy was assessed using skin prick reactivity tests to common airborne allergens
(Leti, Barcelona, Spain) or, should participants have anergy or refuse the first
method, by inhalant panel testing run on blood samples (Phadiatop, Thermo-
Fisher Scientific, Uppsala, Sweden).
Blood biomarkers
A complete blood count (Advia120, Siemens, Munich, Germany) and a high-
sensitivity C-reactive protein (hs-CRP) test (Dimension EXL200, Siemens, Munich,
Germany) were carried out.
Variables and applied definitions
The pulmonary treatable traits and definitions included in the study were: airflow
limitation (AL; post-bronchodilator z-score FEV1/FVC\21.64),6,20 restrictive
spirometry pattern (z-score FEV1/FVC˜ +1.64 and z-score FVC\21.64),
21 air-
way smooth muscle contraction (bronchodilator reversibility: an increase of ˜12%
and ˜200mL compared to baseline in either FEV1 or FVC)
22 and type-2 airway
inflammation (FeNO .17ppb – proposed cutoff for elderly patients),23 chronic
bronchitis (cough with sputum expectoration for at least 3months a year, for two
consecutive years)20 and arterial hypoxemia (peripheral oxygen
saturation\91%).24 Alternatively, cutoff points for type-2 airway inflammation
were used: Global Initiative for Asthma (GINA) – FeNO ˜20ppb25; and
American Thoracic Society – FeNO .50ppb.26 Taking into consideration that
among some patients with normal lung function, including normal FEV1, forced
mid-expiratory flow (FEF25%–75%) may be an early predictive marker of the devel-
opment of airway obstruction, the frequency of low FEF25%–75% (z-score
\20.8435) was also calculated in patients with normal FEV1 (z-score ˜21.64)
pre-bronchodilation.27
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The extrapulmonary treatable traits considered in this study were: allergic sensi-
tisation (at least one positive skin prick test to common airborne allergens or a pos-
itive inhalant panel), anaemia (World Health Organisation definition: haemoglobin
levels \13 g/dL for men and \12 g/dL for non-pregnant women21), obesity (body
mass index ˜30kg/m2),28 patients being underweight (body mass index \18.5 kg/
m2),28 cognitive impairments (participants who scored below the validated cutoff
points for the Portuguese population in either of the cognitive screening tests -
MMSE: 22 for 0–2 years of schooling; 24 for 3–6 years and 27 for 7 years),14 depres-
sion (GDS-15. 5)29 and chronic systemic inflammation (hs-CRP .3mg/L).30 The
behavioural/lifestyle risk factor evaluated was smoking, defined as more than 20-
pack-year smoking history.20
Statistical analysis
An exploratory analysis of the variables of interest was carried out for the entire
sample. Fisher Exact tests were used to compare differences between categorical
variables. A logistic regression was performed to examine the association between
extrapulmonary and behavioural/lifestyle treatable traits and an airflow limitation
or a restrictive spirometry pattern. The presence of an airflow limitation or restric-
tive spirometry pattern constituted the outcomes of interest. Age, sex and extrapul-
monary and behavioural/lifestyle treatable traits were the exposures considered for
the study.
The variables with a p-value \0.25 in the bivariate logistic regression analysis
were selected for the multivariate logistic regression analysis. The level of signifi-
cance used was 0.05, although p-values greater than 0.05 and lower than 0.1 were
still considered to indicate evidence. Data analysis was performed using STATA
(Stata Statistical Software: Release 12; StataCorp LP, Lakeway, TX, USA).
Results
For this study, 1034 residents were screened with 234 meeting the inclusion criteria
and being able to complete all the assessments planned. An inability to participate
was mostly due to a lack of cognitive and collaborative capabilities. The median
age of participants was 86.3 (IQR: 7.4), and an overwhelming percentage were
women (72%; p\ 0.0001). Among patients assessed, 105 (44.9%; 95% CI:
39.0–51.0) had at least one pulmonary treatable trait, and 17.1% had two or more.
The frequency of treatable traits identified is presented in Table 1. Among the
patients with pre-bronchodilation normal FEV1 (n=121), 76 (62.8%) had a low
FEF25%–75%.
The overlap of participants with airflow limitation, airway smooth muscle con-
traction and type-2 airway inflammation is shown in Figure 1. When alternative
cutoff points for FeNO were used, different frequencies of patients were found:
GINA FeNO ˜20ppb: 25.6%; and American Thoracic Society – FeNO .50ppb:
2.6%. Of patients with type-2 airway inflammation (n=69; 29.5%), 23.2% had
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Airflow limitation 10.3 18.5 7.1 0.02
Restrictive spirometry pattern 13.2 13.8 13.0 0.83
Airway smooth muscle contraction 13.7 10.8 14.8 0.53
Type-2 airway inflammation 29.5 24.6 31.4 0.34
Chronic bronchitis 15.4 12.3 16.6 0.55
Arterial hypoxemia 1.3 1.5 1.2 1.00
Extra-pulmonary treatable traits
Allergic sensitisation 20.9 32.8 16.3 0.01
Chronic systemic inflammation 47.0 55.4 43.8 0.14
Anaemia 34.4 46.9 29.4 0.02
Obesity 27.4 15.4 32.0 0.01
Underweight 1.7 1.5 1.8 1.00
Depression 32.5 26.2 34.9 0.22
Cognitive impairment 20.5 13.8 23.1 0.15
Behavioural/lifestyle risk factors treatable traits
Smoking 10.7 30.8 3.0 \0.01
All the results are expressed in %.
Bold values are statistically significant.
*x2 test.
Figure 1. Overlap of participants with airflow limitation, airway smooth muscle contraction
and type-2 airway inflammation.
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allergic sensitisation and 4.3% had an airflow limitation. Among patients with an
airflow limitation (n=24; 10.3%), 37.5% also had airway smooth muscle contrac-
tion, 12.5% had concurrent type-2 airway inflammation, and 8.3% had all three
coexisting treatable traits.
The frequencies of treatable traits identified in the extrapulmonary and beha-
vioural/risk factor domains are presented in Table 1. Those most frequently identi-
fied were: persistent systemic inflammation, anaemia, depression and obesity.
In the sample evaluated, airflow limitation was only significantly linked to smok-
ing of the treatable traits in the extrapulmonary or behavioural/risk factor domains
included in the analysis. The associations between airflow limitation and the extra-
pulmonary and behavioural/risk factor treatable traits identified are presented in
Table 2.
Furthermore, a restrictive spirometry pattern (n=31; 13.2%) was associated
with cognitive impairment. The association between a restrictive spirometry pat-
tern and obesity almost fulfilled the statistical significance criteria. Table 3 presents
the associations between a restrictive spirometry pattern and the extrapulmonary
and behavioural/risk factor treatable traits identified.
Discussion
In the sample evaluated, a significant number of individuals presented with pul-
monary and extrapulmonary treatable traits. A novel association was found
between a restrictive spirometry pattern and cognitive impairment. As expected, a
large majority of women (72%)1 was present in the sample evaluated. On a global
level, between 2015 and 2020, life expectancy at birth for women exceeds that of
men by 4.8 years in Europe, and by 6.1 years in North America.1 Projections
Table 2. Associations between airflow limitation and the extrapulmonary and behavioural/risk









0.95 (0.41–2.21) 0.90 – –
Allergic sensitisation 2.07 (0.83–5.19) 0.12 2.10 (0.78–5.68) 0.14
Anaemia 1.42 (0.60–3.36) 0.43 – –
Obesity 0.35 (0.10–1.21) 0.10 0.35 (0.09–1.33) 0.12
Depression 0.51 (0.18–1.44) 0.20 0.69 (0.23–2.03) 0.50
Cognitive impairment 0.76 (0.24–2.32) 0.62 – –
Behavioural/lifestyle risk factors treatable traits
Smoking 5.68 (1.70–15.17) \0.01 5.03 (1.56–16.22) \0.01
CI: confidence interval; OR: odds-ratio.
*Adjustment for sex (OR: 2.96; p = 0.01); age was not significantly associated.
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indicate that in 2050, women will comprise 54% of the global population aged 65
or over. However, as the sex gap in survival rates between men and women is nar-
rowing, the sex balance among persons aged 80 or over will start to even out.1
In the sample evaluated, almost half of the individuals (44.9%) had a pulmonary
treatable trait. This fact is in concordance with an ageing global population among
which CRDs are becoming a prominent cause of disease.31 From the pulmonary
treatable traits evaluated, type-2 airway inflammation was the most frequently
identified (29.5%), although its unexpectedly high prevalence might be related to
the relatively low cutoff applied (17 ppb).23 The alternative FeNO cutoff point pro-
posed by GINA25 (˜20ppb) identified a similar number of patients (25.6%) with
high FeNO. The percentage of patients identified dropped to 2.6% when the
American Thoracic Society’s26 proposed cutoff for high FeNO (.50ppb) was
applied. It must be emphasised that the alternative cutoffs proposed for FeNO are
tendentiously higher and non-specific to elderly patients when compared with the
one chosen.25 These results emphasise the need for large population studies to be
carried out, in order to strengthen evidence relating to use of this biomarker among
this age group. In the sample evaluated, patients with type-2 airway inflammation
had a relatively low proportion of allergic sensitisation (23.2%) and airflow limita-
tion (4.3%). If the cutoff used is considered to be trustworthy, it could be specu-
lated that type-2 airway inflammation is frequent in very elderly patients, although
rarely associated with allergic mechanisms. Immunosenescence and inflammageing
mechanisms relating to the ageing process collectively change innate and adaptive
immune responses, with several clinical implications.32 Among elderly patients,
these implications include decreased vaccination response rates and increased infec-
tion rates, as well as altered airways and systemic inflammation.32 Higher levels of
neutrophils with increased interleukin (IL)-6, IL-8 and C-reactive protein are fre-
quently found among this age group, resembling changes seen in certain severe
Table 3. Associations between restrictive spirometry pattern and the extrapulmonary and







Chronic systemic inflammation 1.44 (0.67–3.07) 0.35 – –
Allergic sensitisation 0.90 (0.35–2.33) 0.82 – –
Anaemia 1.46 (0.67–3.15) 0.34 – –
Obesity 2.15 (0.99–4.70) 0.05 2.16 (0.95–4.91) 0.07
Depression 1.37 (0.63–2.99) 0.43 – –
Cognitive impairment 2.47 (1.09–5.59) 0.03 3.49 (1.42–8.58) \0.01
Behavioural/lifestyle risk factors treatable traits
Smoking 1.28 (0.41–4.03) 0.67 – –
CI: confidence interval; OR: odds-ratio.
Bold values are statistically significant.
*Adjustment for age (OR: 0.89; p \ 0.01); sex was not significantly associated.
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asthma phenotypes, which are often less responsive to corticosteroid treatment.32
In the absence of allergic mechanisms, eosinophilic inflammation can still arise in
response to epithelial damage from inhaled pollutants and microbes.33 The epithe-
lial alarmins typically released in response to airway epithelial damage promote
type-2 airway inflammation independently of allergic mechanisms.33 In the sample
analysed, a significant proportion of individuals (62.8%) with normal baseline
FEV1 had low FEF25-75% values. Despite the debate surrounding the clinical rele-
vance of this parameter,34 recent evidence postulates that these patients should be
monitored carefully, even if they have normal lung function, as they might have an
increased incidence rate of COPD in the future.27
A high burden of several extrapulmonary treatable traits was found in the sam-
ple evaluated, namely persistent systemic inflammation, anaemia, depression and
obesity. Anaemia was found to be very frequent (34.4%), and previous reports have
also shown that the frequency of anaemia increases with age, especially in elderly
men, and exceeds 20% in very elderly patients.35 Among this age group, anaemia is
typically caused by an underlying aetiology, such as a chronic disease, iron defi-
ciency or myelodysplastic syndromes that can be identified through further investi-
gation.35 In this study, the underlying causes of anaemia were not investigated as
this was not one of the objectives of the study, but all the information was shared
with patients, in order to assist their doctors.
Depression is frequently detected among elderly people, but it is not a normal
consequence of ageing.36 The prevalence of depression in the sample evaluated
(32.5%) is higher than that published for elderly individuals in general.36 This fact
might be explained by known considerably higher rates of depression among very
elderly patients compared to elderly people in general, and among institutionalised
older adults.36 Assertive approaches to diagnosis and treatment are necessary to
improve overall functioning and prevent suicide.36 The obesity rate of this sample
was similar to what has been published in other studies.37 In this study, however,
obesity proved to be almost twice as frequent in women than in men (32.0 vs 15.4;
p=0.01), contrary to other studies.37 Possible explanations for these variations
may be related to the relationship between obesity and living place, degree of rural-
ity, socioeconomic status and geography.37 Survival-related bias must also be taken
into consideration when comparing very elderly patients with elderly patients in
general.
In the sample analysed, airflow limitation was only significantly associated with
smoking (adjusted odds-ratio 3.82; p=0.02), of the extrapulmonary or beha-
vioural/risk factor treatable traits included in the analysis. Smoking was a treatable
trait found in 10.3% of the elderly participants, though it was far more frequent
among men (29.2% vs 3.0% in women; p\ 0.01). Smoking has been defined as
one of the greatest public health disasters of the 20th century.38 Published reviews
have summarised thousands of studies linking smoking to a host of adverse health
conditions, including cardiovascular disease, dementia, adverse reproductive out-
comes, cancer and respiratory diseases.38 Guidelines recommend that clinicians
screen individuals who have at least a 20-pack-year smoking history, as defined in
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this study as a treatable trait.20 Smoking can affect airways by inducing tissue dam-
age both directly, through oxidative stress, and indirectly, by eliciting an inflamma-
tory response.39 The severity of airflow limitation is associated with the extent to
which lung tissue damage has occurred.39 Airway remodelling thickens airway
walls in a manner that involves the epithelium, lamina propria, smooth muscle and
adventitia of airway walls that have a diameter of less than 2mm.39 Regarding the
epidemiology of smoking, as a treatable trait, it is a well-known fact that far more
men than women use tobacco products.39 Participants of this study were mostly
born in the early 20th century, when smoking was a habit observed far more fre-
quently among men. As such, this result met expectations. However, the epidemic
of tobacco use among women is increasing, which means this sex gap will likely
diminish.40 The epidemic of smoking among women should draw the attention of
all in the future.
A restrictive spirometry pattern was found in 13.2% of the participants in this
study. This treatable trait frequency was comparable to that found in previous
studies carried out with similar populations and evaluative methods.41 The restric-
tive spirometry pattern was significantly associated with cognitive impairment. In
this study, obesity was not linked to a restrictive spirometry pattern (adjusted
odds-ratio: 2.16; p=0.07), although the respiratory consequences of being over-
weight are well established.42 Patients present with predominantly mechanical con-
sequences, though an inflammatory component is also present.42 Adiposity on the
thoracic cage and abdomen can affect chest wall movement, airway size, respira-
tory muscle function and lung perfusion.42 From a public health perspective, it is
fundamental to encourage lifestyle changes in elderly patients. Physicians will need
to balance the potential danger of weight loss in older persons against the compli-
cations of obesity in order to decide on the best patient-centred approach. One
clear recommendation is that all weight loss regimens in the elderly need to be
coupled with a comprehensive resistance exercise program.
The results of this study excitingly support recent evidence about the link
between restrictive pattern and cognitive impairment (adjusted odds-ratio: 3.89;
p\ 0.01). As previously published by Lutsey et al., 43 restrictive spirometry pattern
has been linked to cognitive impairment independently of smoking status and was
more pronounced than in patients with airflow limitation. The evidence available
supports the hypothesis that there is a link between restrictive spirometry pattern
and cognitive impairment, both for Alzheimer’s disease and cerebrovascular aetiol-
ogies, although this was not evaluated in this study.43 Restrictive impairment
patients tend to have ventilation-perfusion mismatch and hypoxemia, although
further research is needed in order to gain an understanding of the full mechanisms
involved.43
This study has some limitations that may be prejudicial to conclusions.
Although the OLDER study was a one-year prospective cohort study, the analysis
included in this paper was only cross-sectional, using patients’ baseline data.
Additionally, the sample of participants was not large enough to find a consider-
able number of patients with pulmonary treatable traits. Furthermore, we do not
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know to what extent these results could be extrapolated to the general population,
as the participants were recruited in ECC and a large number of participants were
considered ineligible. The major strengths of our study are the inclusion of a care-
fully selected sample of very old persons recruited in a non-clinical setting, a
detailed clinical characterisation of terms and the precise definition of treatable
traits in very elderly patients. To the best of the authors’ knowledge, this is the first
study providing such information, finding associations between pulmonary, extra-
pulmonary and behavioural/lifestyle risk factors in this age group.
Conclusions
Very elderly patients have a high burden of several differing treatable traits. Almost
half of the individuals tested had a pulmonary treatable trait, a prominent issue
among an ageing population. This study contributes exciting new data about the
association between a restrictive spirometry pattern and cognitive impairment.
Clinical research about elderly patients is fundamental to providing proper care to
a particularly vulnerable age group.
Acknowledgements
The authors would like to express their gratitude to all participants and caregivers for their
essential contributions. The authors would also like to thank all nursing home staff members
for their collaboration. We would also like to acknowledge the help provided by Augusta
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